The REDUCE follow-up study: Low rate of new prostate cancer diagnoses observed during a 2-year, observational, followup study of men who participated in the REDUCE trial

Journal of Urology

Volumn 189, Issue 3, 2013, Pages 871-877

  Grubb, Robert L ^a   Andriole, Gerald L ^a   Somerville, Matthew C ^b   Mahoney, Chrysa ^b   Manyak, Michael J ^b   Castro, Ramiro ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

biopsy; diagnosis; dutasteride; neoplasm grading; prostatic neoplasms

Indexed keywords

DUTASTERIDE; PLACEBO;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; BREAST DISEASE; CANCER DIAGNOSIS; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN TISSUE; IMPOTENCE; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; RISK REDUCTION; TELECONSULTATION; URINE RETENTION;

5-ALPHA REDUCTASE INHIBITORS; AGED; AGED, 80 AND OVER; AZASTEROIDS; BIOPSY; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84873704282     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.09.099     Document Type: Article

References (12)

1. G.L. Andriole, D.G. Bostwick, O.W. Brawley Effect of dutasteride on the risk of prostate cancer N Engl J Med 362 2010 1192
2. I.M. Thompson, P.J. Goodman, C.M. Tangen The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215
3. M.S. Lucia, J.I. Epstein, P.J. Goodman Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial J Natl Cancer Inst 99 2007 1375
4. M.W. Redman, C.M. Tangen, P.J. Goodman Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach Cancer Prev Res (Phila) 1 2008 174
5. I.M. Thompson, C. Chi, D.P. Ankerst Effect of finasteride on the sensitivity of PSA for detecting prostate cancer J Natl Cancer Inst 98 2006 1128
6. C.A. Pettaway, J.C. Nickel, M. Marberger Efficacy of dutasteride in men with low prostate volume in the REduction by DUtasteride of prostate Cancer Events (REDUCE) study J Urol 185 suppl. 2011 e855 abstract 2136
7. M.R. Theoret, Y.M. Ning, J.J. Zhang The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention N Engl J Med 365 2011 97
8. D.F. Gleason Classification of prostatic carcinomas Cancer Chemother Rep 50 1966 125
9. J.D. Kalbfleisch, R.L. Prentice The Statistical Analysis of Failure Time Data 2002 John Wiley & Sons, Inc Hoboken
10. H.G. Welch, E.S. Fisher, D.J. Gottlieb Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era J Natl Cancer Inst 99 2007 1395
11. B. Djavan, V. Ravery, A. Zlotta Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 166 2001 1679
12. P.H. Gann, A. Fought, R. Deaton Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach J Clin Oncol 28 2010 1714